| Name | Avacta Group |
|---|---|
| Epic | AVCT |
| Isin | GB00BYYW9G87 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 64.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £231.58 | Debt ratio | n/a |
| Shares in issue | 359.04 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -71.6 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -15.48 | 52-week high / low | 39.75p / 159.60p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Avacta Group |
|---|---|
| Address | Unit 20, Ash Way, Thorp Arch Estate, Wetherby, United Kingdom, LS23 7FA |
| Telephone | +44 (0)1904 21 7070 |
| Website | http://www.avacta.com |
| Director | Position |
|---|---|
| Ms Christina Coughlin | CEO |
| Mr Tony Peter Gardiner | CFO |
| Mr Paul Fry | Non-Executive Director |
| Mr Shaun Chilton | Non-Executive Director |
| Dr Mark Goldberg | Non-Executive Director |
| Dr Trevor Nichols | Non-Executive Director |
| Dr Eliot Forster | Non-Executive Chairman |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 26.32 | 7.92 | 9.42 |
| Investments and other non-current assets | 2.98 | n/a | n/a |
| Total non-current assets | 37.1 | 12.27 | 14.21 |
| Inventory / work in progress | 1.68 | 0.19 | 0.25 |
| Trade and other receivables | 12.09 | 7.08 | 2.89 |
| Cash and equivalents | 41.78 | 26.19 | 27.89 |
| Other current assets and asset held for resale | n/a | 1.28 | 22.22 |
| Total of all assets | 92.65 | 47 | 67.46 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 67.61 | 4.37 | 3.78 |
| Long term liabilities | 6.6 | 1.41 | 1.75 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 74.21 | 5.78 | 5.53 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 18.44 | 41.22 | 61.93 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 26.68 | 25.47 | 25.34 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -66 | -34.09 | -12.86 |
| Share premium account | 62.18 | 54.53 | 54.14 |
| Total equity | 18.44 | 41.22 | 61.93 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -31.49 | -29.08 | -18.81 |
| Pre-tax profit | -41.46 | -29.19 | -18.86 |